Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Letetresgene autoleucel (Primary)
- Indications Liposarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors GSK
Most Recent Events
- 22 Oct 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 21 Aug 2023 New trial record